Assessment of prescribing practices in overactive bladder pharmacotherapy across different specialties of India: a prescription trend analysis


Cite item

Full Text

Abstract

Purpose: To assess the prescribing practices for overactive bladder (OAB) pharmacotherapy based on the prescription trend analysis across different specialties of India.

Methods: IQVIA (Quintiles and IMS Health) secondary sales audit (SSA), as well as a prescription audit for antimuscarinics and beta-3 adrenoceptor agonists (mirabegron) from 2014 to 2021, were analyzed. The data includes SSA data of various antimuscarinics like solifenacin, oxybutynin, tolterodine, darifenacin, trospium and mirabegron change in the prescription trend of antimuscarinics and mirabegron across different specialties; prescribers overlap analysis for solifenacin and mirabegron among Indian urologists were also analyzed.

Results: Urologists’ prescription rates of OAB drugs were 65% in 2016 and 54% in 2021. The rate of OAB medication prescription by non-urologist was highest from the surgeon (11%), followed by gynecologists (9%) and consultant physicians (8%) in 2021. In addition, among OAB medication prescription rates for antimuscarinics were 100% in 2016 and 58% in 2021 whereas for mirabegron, it was 0% in 2016 and 42% in 2021. Solifenacin was most frequently prescribed anticholinergics, followed by oxybutynin, tolterodine, darifenacin, and trospium. The proportion of prescribers of OAB medication among urologists was 38% in 2016 and 33% in 2021. Exclusive prescribers of solifenacin were 748 in 2018 and 739 in 2021 at the urologist, whereas for mirabegron, it was 961 in 2018 and 934 in 2021. The compound annual growth rate for prescription of the last 6 years (from 2016-2021) for solifenacin and mirabegron was -3% and 8% respectively.

Conclusions: Urology remained a top prescribing specialty for OAB drugs, although prescription share increased at surgeon and consultant physician. OAB medicines prescriptions by urologists are shifting from leading antimuscarinic solifenacin to beta-agonist mirabegron. Data from this study will ultimately lead to the OAB medication preference by the specialist that could lead to more advanced OAB management.

Full Text

Restricted Access

About the authors

Vishavadia Krunal

Gujarat Technological University

Author for correspondence.
Email: krunalvishavadia@gmail.com
India, Ahmedabad

Solanki Sandip

SIIB

Email: sandip.solanki@siib.ac.in
India, Pune, Maharashtra

Prajapati Hiren

International Journal of Diabetes and Endocrinology

Email: hiprajapati4042@gmail.com

Editorial Board Member

India, Ahmedabad, Gujarat

Sharma Madhu

Sardar Vallabhbhai Patel Institute of Medical Science and Research

Email: dr.madhusharma90@gmail.com

Department of Anaesthesiology

India, Ellisbridge, Ahmedabad, Gujarat

References

  1. Wróbel, A. Overactive bladder syndrome pharmacotherapy: future treatment options. Menopausal Rev. 2015;4:211–217.
  2. Lee U.J. et al. Defining and Managing Overactive Bladder: Disagreement Among the Experts. Urology. 2013;81:257–262.
  3. Irwin D. E. et al. Population-Based Survey of Urinary Incontinence, Overactive Bladder, and Other Lower Urinary Tract Symptoms in Five Countries: Results of the EPIC Study. Eur. Urol. 2006;50:1306–1315.
  4. Moorthy P., Lapitan M. C., Quek P. L. C., Lim P.H. C. Prevalence of overactive bladder in Asian men: an epidemiological survey. BJU Int. 2004;93:528–531.
  5. Sinha S. et al. The urological society of India guidelines for the evaluation and management of nonneurogenic urinary incontinence in adults (executive summary). Indian J. Urol. 2019;35:185–188.
  6. Gulur D.M., Drake M.J. Management of overactive bladder. Nat. Rev. Urol. 2010;7:572–582.
  7. Central Drugs Standard Control Organization. CDSCO List of Approved New Drugs. 2021. Available at: https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/. (Accessed: 3rd June 2021)
  8. Gormley E.A. et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J. Urol. 2012;188:2455–2463.
  9. Chilman Blair K., Bosch J.L. Solifenacin: Treatment of overactive bladder. Drugs of Today. 2004;40:343.
  10. Mandpe P., Prabhakar B., Shende P. Potential of Mirabegron and its Extended-release Formulations for the Treatment of Overactive Bladder Syndrome. Curr. Drug Metab. 2020;21:79–88.
  11. Sinha S. et al. The Urological Society of India survey on urinary incontinence practice patterns among urologists. Indian J. Urol. 2018;34:202–210.
  12. Candore G. et al. Can We Rely on Results From IQVIA Medical Research Data UK Converted to the Observational Medical Outcome Partnership Common Data Model? Clin. Pharmacol. Ther. 2020;107:915–925.
  13. Farooqui H.H., Mehta A., Selvaraj S. Outpatient antibiotic prescription rate and pattern in the private sector in India: Evidence from medical audit data. PLoS One. 2019;14:1–11.
  14. WHO. International Statistical Classification of Diseases and Related Health Problems (ICD). 2016. Available at: https://icd.who.int/browse10/2016/en. (Accessed: 9th June 2021)
  15. CDSCO. Recommendations of the SEC (Reproductive & Urology) made in its 25.2017; 6–8.
  16. IQVIA India. IQVIA Industry Highlights AUG-20. IQVIA Inst. Hum. Data Sci. 2000;5.
  17. Kelleher C. et al. Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis. Eur. Urol. 2018;74:324–333.
  18. Yeowell G. et al. Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review. BMJ Open 2018;8:e021889.
  19. Chapple C. R. et al. Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice. Eur. Urol. 2017;72:389–399.
  20. Wagg A.S. et al. Persistence and adherence with mirabegron vs antimuscarinics in overactive bladder: Retrospective analysis of a UK General Practice prescription database. Int. J. Clin. Pract. 2017;71:e12996.
  21. Batista J.E. et al. The efficacy and safety of mirabegron compared with solifenacin in overactive bladder patients dissatisfied with previous antimuscarinic treatment due to lack of efficacy: results of a noninferiority, randomized, phase IIIb trial. Ther. Adv. Urol. 2015;7:167–179.
  22. Wagg A., Compion G., Fahey A., Siddiqui E. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. BJU Int. 2012;110:1767–1774.
  23. Maman, K. et al. Comparative efficacy and safety of medical treatments for the management of overactive bladder: A systematic literature review and mixed treatment comparison. Eur. Urol. 2014;65:755–765.
  24. Liao C.-H., Kuo H.-C. High satisfaction with direct switching from antimuscarinics to mirabegron in patients receiving stable antimuscarinic treatment. Medicine (Baltimore). 2016;95:e4962.
  25. Krebs J., Pannek J., Rademacher F., Wöllner J. Real-World Effects of Mirabegron in Patients with Chronic Neurogenic Detrusor Overactivity – A Retrospective Cohort Study. Res. Reports Urol. 2020;12:187–192.
  26. CDSCO. Recommendations of the SEC (Reproductive & Urology) made in its 59th meeting. Cent. Drugs Stand. Control Organ. 2021;6–8.
  27. Gratzke C. et al. Long-term Safety and Efficacy of Mirabegron and Solifenacin in Combination Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II). Eur. Urol. 2018;74:501–509.
  28. Allison S.J., Gibson W. Mirabegron, alone and in combination, in the treatment of overactive bladder: real-world evidence and experience. Ther. Adv. Urol. 2018;10:411–419.
  29. Nazir, J. et al. Cost-Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in the United Kingdom. Value Heal. 2015;18:783–790.
  30. Alana Biggers M.D. Overactive Bladder (OAB) Complications. Healthline. 2017. Available at: https://www.healthline.com/health/overactive-bladder-complications.
  31. Liu R.-T. et al. Prevalence of Overactive Bladder and Associated Risk Factors in 1359 Patients With Type 2 Diabetes. Urology. 2011;78:1040–1045.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Figure 1. Speciality wise prescriber's contribution for OAB drugs in India (2016-2021)

Download (74KB)
Indexing metadata
3. Figure 2. % Prescription and Prescriber share of beta-3 andrenoceptor agonist and antimuscarinics (2017-2021)

Download (165KB)
Indexing metadata
4. Figure 3. Prescription share of OAB drugs at Urologist specialty (2016-2021)

Download (94KB)
Indexing metadata
5. Figure 4. Exclusive prescriber (urologist) analysis for Solifenacin and Mirabegron

Download (68KB)
Indexing metadata

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies